Heart Rate Control in an Unselected Consecutive Population of Outpatients With Stable Coronary Artery Disease: Analysis of the CARDIf Study Cohort

Angiology

Volumn 61, Issue 8, 2010, Pages 763-767

  Vitale, Cristiana ^a   Iellamo, Ferdinando ^a,b   Volterrani, Maurizio ^a   Lombardi, Mariaelena ^a   Fini, Massimo ^a   Banach, Maciej ^c   Rosano, Giuseppe M c ^a  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

coronary artery disease; heart failure; heart rate; myocardial revascularization; survey; blockers

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

AGED; ARTICLE; BODY MASS; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDY; FEMALE; HEART FAILURE; HEART RATE; HUMAN; MALE; MULTICENTER STUDY; PATHOPHYSIOLOGY; SEXUAL DEVELOPMENT; SMOKING;

ADRENERGIC BETA-ANTAGONISTS; AGED; BODY MASS INDEX; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; HEART FAILURE; HEART RATE; HUMANS; MALE; SEX CHARACTERISTICS; SMOKING;

EID: 78049446722     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/0003319710369102     Document Type: Article

References (33)

1. Fox K, Borer JS, Camm JA, et al; for the Heart RateWorking Group. Resting heart rate in cardiovascular disease. J Am Coll Cardiol. 2007;50(9):823-830.
2. Mensink GB, Hoffmeister H. The relationship between resting heart rate and all-cause cardiovascular and cancer mortality. Eur Heart J. 1997;18(9):1404-1410.
3. Wikstrand J, Berglund G, Hedblad B, Hulthe J. Antiatherosclerotic effects of beta-blockers. Am J Cardiol. 2003;91(12A):25-29.
4. Kannel WB, Kannel C, Paffenbarger RS Jr, Cupples LA. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J. 1987;113(6):1489-1494.
5. Gillum RF, Makuc DM, Feldman JJ. Pulse rate, coronary heart disease, and death: the NHANES I Epidemiologic Follow-up Study. Am Heart J. 1991;121(1 pt 1):172-177.
6. Palatini P, Julius S. Elevated heart rate: a major risk factor for cardiovascular disease. Clin Exp Hypertens. 2004;26(7-8):637-644.
7. Lechat P, Hulot JS, Escolano S, et al. Heart rate and cardiac rhythm relationship with bisoprolol benefit in chronic heart failure in CIBIS II trial. Circulation. 2001;103(10):1428-1433.
8. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R; BEAUTIFUL investigators. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet. 2008;372(9641):817-821.
9. Baumhäkel M, Müller U, Böhm M. Influence of gender of physicians and patients on guideline-recommended treatment of chronic heart failure in a cross-sectional study. Eur J Heart Fail. 2009;11(3):299-303.
10. de Groote P, Isnard R, Assyag P, et al. Is the gap between guidelines and clinical practice in heart failure treatment being filled? Insights from the IMPACT RECO survey. Eur J Heart Fail. 2007;9(12):1205-1211.
11. Kovar D, Cannon CP, Bentley JH, Charlesworth A, Rogers WJ. Does initial and delayed heart rate predict mortality in patients with acute coronary syndromes? Clin Cardiol. 2004;27(2):80-86.
12. Jouven X, Empana J-P, Schwartz PJ, Desnos M, Courbon D, Ducimetiere P. Heart-rate profile during exercise as a predictor of sudden death. N Engl J Med. 2005;352(19):1951-1958.
13. Diaz A, Bourassa MG, Guertin M-C, Tardif J-C. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J. 2005;26(10):967-974.
14. Eagle KA, Lim MJ, Dabbous OH, et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA. 2004;291(22):2727-2733.
15. Marchioli R, Avanzini F, Barzi F, et al. Assessment of absolute risk of death after myocardial infarction by use of multiple-riskfactor assessment equations: GISSI-Prevenzione mortality risk chart. Eur Heart J. 2001;22(22):2085-2103.
16. Morrow DA, Antman EM, Charlesworth A, et al. TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation. 2000;102(17):2031-2037.
17. Janssen I, Katzmarzyk PT, Church TS, Blair SN. The Cooper Clinic mortality risk index: clinical score sheet for men. Am J Prev Med. 2005;29(3):194-203.
18. Swedberg K. Pure heart rate reduction: further perspectives in heart failure. Eur Heart J Suppl. 2007;9(suppl F):F20-F24.
19. Aaronson KD, Schwartz JS, Chen TM, Wong KL, Goin JE, Mancini DM. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation. 1997;95(12):2660-2667.
20. Hjalmarson A. Heart rate: an independent risk factor in cardiovascular disease. Eur Heart J Suppl. 2007;9(suppl F):F3-F7.
21. Kowalski J, Banach M, Barylski M, Irzmanski R, Pawlicki L. Carvedilol modifies antioxidant status of patients with stable angina. Cell Mol Biol Lett. 2008;13(2):230-239.
22. McAlister FA, Wiebe N, Ezekowitz JA, Leung AA, Armstrong PW. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med. 2009;150(11):784-794.
23. Cucherat M. Quantitative relationship between resting heart rate reduction and magnitude of clinical benefits in post-myocardial infarction: a metaregression of randomized clinical trials. Eur Heart J. 2007;28(4):3012-3019.
24. MERIT-HF Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). Lancet. 1999;353(9169):2001-2007.
25. Kjekshus JK. Importance of heart rate in determining betablocker efficacy in acute and long-term acute myocardial infarction intervention trials. Am J Cardiol. 1986;57(12):43F-49F.
26. Gundersen T, Grottum P, Pedersen T, Kjekshus JK. Effect of timolol on mortality and reinfarction after acute myocardial infarction: prognostic importance of heart rate at rest. Am J Cardiol. 1986;58(1):20-24.
27. Metra M, Torp-Pedersen C, Swedberg K, et al. Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial. Eur Heart J. 2005;26(21):2259-2268.
28. Rochon PA, Anderson GA, Tu JV. et al. Use of β-blocker therapy in older patients after acute myocardial infarction in Ontario. Can Med Assoc J. 1999;161(11):1403-1408.
29. Simpson E, Beck C, Richard H, Eisenberg MJ, Pilote L. Drug prescriptions after acute myocardial infarction: dosage, compliance, and persistence. Am Heart J. 2003;145(3):438-444.
30. Tandon P, McAllister FA, Tsuyuki RT, et al. The use of betablockers in a tertiary care heart failure clinic: dosing, tolerance, and outcomes. Arch Intern Med. 2004;164(7):769-774.
31. Mehta PA, McDonagh S, Poole-Wilson PA, Grocott-Mason R, Dubrey SW. Heart failure in a district general hospital: are target doses of beta-blockers realistic? QJM. 2004;97(3):133-139.
32. Komajda M, Follath F, Swedberg K. et al; for the Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The EuroHeart Failure Survey programme—a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J. 2003;24(5):464-474.
33. Giannoglou GD, Chatzizisis YS, Zamboulis C, Parcharidis GE, Mikhailidis DP, Louridas GE. Elevated heart rate and atherosclerosis: an overview of the pathogenetic mechanisms. Int J Cardiol. 2008;126(3):302-312.